iiinova — where your digital self keeps evolving

Amber Tong @ambertongpw.bsky.social · 02/05/2025

wow - Charles Lieber, the retired Harvard University chemist convicted in 2021 for not disclosing his China ties, joined Tsinghua University as a chair professor www.scmp.com/news/china/s...

scmp.com

Former Harvard professor convicted over China ties joins Tsinghua University

Chemist and nanoscientist Charles Lieber says he aims to ‘realise more scientific dreams in the vibrant and innovative city of Shenzhen’.

021

Amber Tong @ambertongpw.bsky.social · 22/01/2025

Misunderstanding of drug labels can be dangerous for the patient and costly for the healthcare system. I visited a social enterprise in Hong Kong trying to prevent that by promoting traffic sign-like icons: www.bloomberg.com/news/newslet...

bloomberg.com

Traffic-Sign Like Icons to Help Simplify Drug Labels for the Layperson

Hi, it’s Amber in Hong Kong. For many of us, drug labels can be impossible to decipher. A small change may help. But before I explain…

000

Amber Tong @ambertongpw.bsky.social · 24/12/2024

Ascentage Pharma, which scored an option deal and equity investment from Takeda earlier this year, is another step closer to a Nasdaq IPO after securing a listing notice from the China Securities Regulatory Commission. The US-China biotech is developing targeted cancer therapies

010

Amber Tong @ambertongpw.bsky.social · 20/12/2024

ADC assets from WuXi Biologics revive a struggling US biotech: Aadi Bioscience, which laid off the majority of its staff in August after disappointing results, "transforms" by licensing 3 ADCs from WuXi and Hangzhou DAC, selling its only commercial drug for $100M and raising another $100M in a PIPE

210

Amber Tong @ambertongpw.bsky.social · 13/12/2024

Last night, China unveiled latest batch of 62 drugs added to volume-based procurement (VBP) program. The bulk purchase program, which focuses on off-patent drugs, is designed to push prices down Notably, unlike in previous years, authorities didn't disclose the average price cut

100

Amber Tong @ambertongpw.bsky.social · 13/12/2024

Still slowly moving over. For new #biosky friends: I write about the growing role Asia, in particular China, plays on the global business of creating new medicines. I also track the evolving China biopharma market, among other things. Here's a recent story: www.bloomberg.com/news/article...

bloomberg.com

Big Pharma’s Bet on China Biotech Is a Rare Trade Bright Spot

At a time when geopolitical tensions are hitting industries from semiconductors to electric vehicles, pharmaceutical dealmaking has become a rare bright spot for collaboration between China and the We...

020

Amber Tong @ambertongpw.bsky.social · 27/11/2024

Merck partner Kelun Biotech says its TROP2 ADC — the most advanced program in their deal — is approved in China sacituzumab tirumotecan (SKB264/MK-2870) is the first homegrown ADC to win China OK. Merck is running global Phase 3 trials initial indication: 3rd line TNBC

www1.hkexnews.hk

000

Amber Tong @ambertongpw.bsky.social · 21/11/2024

China has pledged to encourage more research in gene and cell therapies at the country’s biotech hub in the eastern Chinese city of Suzhou, in the latest bid to bolster the country’s standing at the cutting edge of global drug research. www.bloomberg.com/news/article...

bloomberg.com

China Vows to Bolster Gene Therapy Research in Key Biotech Hub

010